• Ovarian Cancer
    • Ie‐ming Shih
    • Ie‐Ming Shih: Influence Statistics

      Ie‐Ming Shih

      Ie‐Ming Shih

      Show email address

      Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Medicine, Baltimore, MD, USA | Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD ...

      Is this your profile? manage_accounts Claim your profile content_copy Copy URL code Embed Link to your profile

      Ie‐Ming Shih:Expert Impact

      Concepts for whichIe‐Ming Shihhas direct influence:Ovarian cancer,Serous carcinoma,Ovarian carcinoma,Gene expression,Cancer cells,Grade serous,Ovarian serous,Menstrual cycle.

      Ie‐Ming Shih:KOL impact

      Concepts related to the work of other authors for whichfor which Ie‐Ming Shih has influence:Ovarian cancer,Gene expression,Fallopian tube,Tumor cells,Cell proliferation,Tert promoter mutations,Serous carcinoma.

      KOL Resume for Ie‐Ming Shih


      Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Medicine, Baltimore, MD, USA


      Department of Pathology, Johns Hopkins School of Medicine, Baltimore, MD 21287, United States

      Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA

      Johns Hopkins University, Baltimore, MD;


      Departments of Oncology and Pathology, Johns Hopkins Medical Institutions, Baltimore, MD, USA

      Obstetrics, Johns Hopkins Medical Institutions,

      Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland.


      Gynecologic Pathology Laboratory in the Department of Gynecology and Obstetrics, Johns Hopkins University School of Medicine, Baltimore, MD, USA

      Gynecology and Obstetrics, The Sidney Kimmel Cancer Center, Johns Hopkins Medical Institutions, Baltimore, MD

      Departments of, Oncology

      Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland.


      Massachusetts General Hospital, Harvard University (E.O.), Boston, Massachusetts

      Bellvitge University Hospital, IDIBELL, Barcelona (A.V., X.M.G.)

      Brigham and Women’s Hospital (B.H., B.J.Q.)

      Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.

      The Ottawa Hospital, University of Ottawa, Ottawa (B.D.)

      Sign-in to see all concepts, it's free!
      Sample of concepts for which Ie‐Ming Shih is among the top experts in the world.
      Concept World rank
      latterstage #1
      dna copy length #1
      including ovarian #1
      chipbit #1
      regions 3q #1
      multinucleation cancer cells #1
      rsf1 expression #1
      dysregulated signaling pathways #1
      ist2 cells #1
      adenomyosis lack #1
      phosphorylation egfr substrates #1
      score figo stage #1
      carcinoma arid1a #1
      6 urothelial carcinoma #1
      cohort loss #1
      laser stroma #1
      nac1 nac1 knockdown #1
      adenomyosis epithelium stroma #1
      rsf1 nf #1
      endometriosis arid1a #1
      analysis arid1a #1
      arid1a specimens #1
      accurate identification aberrations #1
      rmc ppc #1
      tumor recurrence annexin #1
      endocervical adenocarcinomas percentage #1
      endometrium endometrioid tumorigenesis #1
      nanotethers #1
      stic lesions #1
      intensity rsf1 expression #1
      brac tramtrack #1
      bcl6 analysis #1
      c17orf64 #1
      carcinomas ovarian #1
      development sbt #1
      choriocarcinoma urothelial carcinoma #1
      findings syk activity #1
      amplified genes genes #1
      znf217 protein expression #1
      arid1a penile scc #1
      ovaryin #1
      therapeutic target tet1 #1
      tumor cercopithecus dna #1
      notch3 ovarian #1
      crosses genetic embryo #1
      invasive mpsc lgsc #1
      invasive mpsc #1
      association histologic grade #1
      mel cd146 #1
      Sign-in to see all concepts, it's free!

      Prominent publications by Ie‐Ming Shih

      KOL-Index: 18313

      Recently, we have proposed a model for the development of ovarian surface epithelial tumors. In this model, all histologic types of surface epithelial tumors are divided into 2 categories designated type I and type II which correspond to 2 pathways of tumorigenesis. Type I tumors include low-grade serous carcinoma, mucinous carcinoma, endometrioid carcinoma, malignant Brenner tumor, and clear cell carcinoma which develop slowly in a stepwise fashion from well-recognized precursors, ...

      Known for Grade Serous | Type Tumors | Atypical Proliferative | Carcinoma Low | Borderline Tumor
      KOL-Index: 17608

      Uterine serous carcinomas typically have a characteristic morphology (papillary architecture, high-grade nuclei) and immunoprofile (diffuse/strong p53 expression, loss of hormone receptor expression) that distinguish them from most endometrial endometrioid carcinomas. However, glandular variants of serous carcinoma can simulate Fédération Internationale de Gynécologie et d'Obstétrique (FIGO) grade 2 endometrioid carcinomas, and some serous carcinomas lack p53 expression and retain ...

      Known for Serous Carcinomas | P16 Expression | Tumor Carcinoma | Endometrial Endometrioid | Situ Hybridization
      KOL-Index: 17231

      OBJECTIVES: ARID1A is a recently identified tumor suppressor participating in chromatin remodeling. Somatic inactivating mutations of ARID1A and loss of its expression occur frequently in ovarian clear cell and endometrioid carcinomas and in uterine endometrioid carcinomas. Because endometriotic epithelium is thought to be the cell of origin of most ovarian clear cell and endometrioid carcinomas, we undertook an analysis of ARID1A expression of these tumors arising within an ...

      Known for Endometrioid Carcinoma | Arid1a Expression | Clear Cell | Tumor Progression | Endometriotic Cyst
      KOL-Index: 17001

      The infrequent association of serous borderline tumors (SBTs) with invasive serous carcinoma has led to the view that SBTs are unrelated to invasive serous carcinoma. Nonetheless, mortality associated with SBTs is generally attributed to malignant transformation, and traditionally these tumors have been designated as "carcinomas of low malignant potential." Previous immunohistochemical studies evaluating p53 expression and molecular genetic studies evaluating mutational status have ...

      Known for P53 Mutations | Grade Carcinomas | Ovarian Serous | New Model | Neoplastic Cystadenocarcinoma
      KOL-Index: 16777

      It has been proposed that the presence of tubal intraepithelial carcinoma (TIC), in association with one-third to nearly half of pelvic serous carcinomas, is evidence of fallopian tube origin for high-grade serous carcinomas that would have been otherwise classified as primary ovarian or peritoneal. To address this hypothesis, we evaluated a series of 114 consecutive pelvic (nonuterine) gynecologic carcinomas at our institution (2006 to 2008) to determine the frequency of TIC in 52 cases ...

      Known for Tubal Origin | Serous Carcinomas | Invasive Carcinoma | Fallopian Tube | Ovarian Neoplasms
      KOL-Index: 16242

      Nucleus accumbens-1 (NAC1), a nuclear factor belonging to the BTB/POZ gene family, is known to have important roles in proliferation and growth of tumor cells and in chemotherapy resistance. Yet, the mechanisms underlying how NAC1 contributes to drug resistance remain largely unclear. We report here that autophagy was involved in NAC1-mediated resistance to cisplatin, a commonly used chemotherapeutic drug in the treatment of ovarian cancer. We found that treatment with cisplatin caused ...

      Known for Ovarian Cancer | Nac1 Drug Resistance | Autophagy Cell | Protein Humans | Cisplatin Treatment
      KOL-Index: 15892

      Nongastrointestinal-type mucinous borderline tumors have been described as displaying endocervical and serous differentiation and hence have been termed "endocervical-type" mucinous borderline tumors, "mixed-epithelial papillary cystadenoma of borderline malignancy of mullerian type," or "atypical proliferative seromucinous tumors." A striking feature of these tumors is their frequent association with endometriosis, which has been reported in a third to a half of cases. This is an ...

      Known for Borderline Tumors | Expression Arid1a | Type Mucinous | Mutational Analysis | Frequent Association
      KOL-Index: 15796

      Both placental site nodule and exaggerated placental site are described as being composed of intermediate trophoblast (IT), yet their morphological features and clinical presentation differ significantly. This study was undertaken to evaluate the morphological and immunohistochemical features of trophoblastic cells in placental site nodules and compare them with the trophoblastic cells in exaggerated placental sites as well as in different anatomic locations in the developing placenta to ...

      Known for Placental Site | Intermediate Trophoblast | Neoplastic Counterpart | Chorionic Type | Clinical Presentation
      KOL-Index: 15119

      BACKGROUND: Uterine cancer is the fourth most common malignancy in women, and uterine serous carcinoma is the most aggressive subtype. However, the molecular pathogenesis of uterine serous carcinoma is largely unknown. We analyzed the genomes of uterine serous carcinoma samples to better understand the molecular genetic characteristics of this cancer.

      METHODS: Whole-exome sequencing was performed on 10 uterine serous carcinomas and the matched normal blood or tissue samples. Somatically ...

      Known for Uterine Serous Carcinoma | Wholeexome Sequencing | Gene Copy | Pik3ca Mutation | Aggressive Subtype
      KOL-Index: 14893

      Activation of mitogen-activated protein kinase (MAPK) occurs in response to various growth stimulating signals and as a result of activating mutations of the upstream regulators, KRAS and BRAF, which can be found in many types of human cancer. To investigate the roles of MAPK activation in tumors harboring KRAS or BRAF mutations, we inactivated MAPK in ovarian tumor cells using CI-1040, a compound that selectively inhibits MAPK kinase, an upstream regulator of MAPK and thus prevents MAPK ...

      Known for Braf Mutations | Activated Protein | Ovarian Serous | Gene Expression | Cyclin D1
      KOL-Index: 14833

      Serous tubal intraepithelial carcinomas (STICs) have been proposed to be the most likely precursor of ovarian, tubal and 'primary peritoneal' (pelvic) high-grade serous carcinoma (HGSC). As somatic mutation of TP53 is the most common molecular genetic change of ovarian HGSC, occurring in more than 95% of cases, we undertook a mutational analysis of 29 pelvic HGSCs that had concurrent STICs to demonstrate the clonal relationship of STICs and HGSCs. In addition, we correlated the ...

      Known for Tp53 Mutations | Clonal Relationship | Serous Carcinoma | Stics Hgscs | Tubal Intraepithelial
      KOL-Index: 14776

      ARID1A is a recently identified tumor suppressor gene that is mutated in approximately 50% of ovarian clear cell and 30% of ovarian endometrioid carcinomas. The mutation is associated with loss of protein expression as assessed by immunohistochemistry. In this study, we evaluated ARID1A immunoreactivity in a wide variety of carcinomas to determine the prevalence of ARID1A inactivation in carcinomas. Mutational analysis of ARID1A was carried out in selected cases. Immunoreactivity was not ...

      Known for Grade Endometrioid | Expression Arid1a | Mutational Analysis | Mutation Loss | Carcinoma Ovarian
      KOL-Index: 14605

      Ovarian serous carcinoma is a highly aggressive neoplastic disease in women. Our previous studies have demonstrated Notch3 gene amplification and upregulation in many ovarian serous carcinomas and Notch pathway activity contributed to drug resistance. Among different Notch3 ligands, Jagged1 is most dominant in ovarian cancer, and Notch3 pathway activity correlated with Jagged1 expression level in ovarian carcinoma tissues. In this study, we found that Jagged1 expression depended on ...

      Known for Jagged1 Expression | Ovarian Cancer | Catenin Signaling | Notch3 Receptors | Small Interfering Receptor
      KOL-Index: 14425

      There is debate as to whether peritoneal implants associated with serous borderline tumours/atypical proliferative serous tumours (SBT/APSTs) of the ovary are derived from the primary ovarian tumour or arise independently in the peritoneum. We analysed 57 SBT/APSTs from 45 patients with advanced-stage disease identified from a nation-wide tumour registry in Denmark. Mutational analysis for hotspots in KRAS and BRAF was successful in 55 APSTs and demonstrated KRAS mutations in 34 (61.8%) ...

      Known for Peritoneal Implants | Mutational Analysis | Braf Mutations | Ovarian Serous | Oncogene Proteins
      KOL-Index: 14296

      The diagnosis of placental site trophoblastic lesions, particularly the distinction of a placental site trophoblastic tumor from an exaggerated placental site, can be difficult. Mel-CAM (also known as CD146 and MUC18) is a recently recognized cell adhesion molecule belonging to the immunoglobin gene superfamily that specifically identifies intermediate trophoblast (IT). In this study, we evaluated immunohistochemical staining of Ki-67 (using Mib-1 antibody) in Mel-CAM defined IT as an ...

      Known for Placental Site | Trophoblastic Tumor | Differential Diagnosis | Immunohistochemical Staining | Ki67 Melcam

      Key People For Ovarian Cancer

      Top KOLs in the world
      Ahmedin M Jemal
      united states breast cancer addis ababa
      Rebecca L Siegel
      united states colorectal cancer incidence rates
      Ignace B P Vergote
      ovarian cancer neoadjuvant chemotherapy advisory consultancy
      Robert C Bast
      ovarian cancer early detection bone marrow
      Beth Young Karlan
      ovarian cancer brca2 mutation brca1 genes
      Anil K Sood
      ovarian cancer tumor growth gene expression

      Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Medicine, Baltimore, MD, USA | Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA;, juliane.liberto@jhmi.edu, (J.M.L.);, ishih@jhmi.edu, (I.-M.S.);,

    Download on the App StoreGet it on Google Play

    Copyright © 2023 Key Opinion Leaders, LLC.